Beijing Scitop Bio Tech Co Ltd

Sci-Tech Bio released its 2026 interim report. Operating revenue was 170 million yuan, up 3.77 percent year on year, but net profit attributable to the parent company was 25.097 million yuan, down 39.09 percent. Net profit after deducting non-recurring items was 18.6817 million yuan, down 46.82 percent, and net cash flow from operating activities was 10.1627 million yuan, down 63.55 percent. Revenue from edible probiotic products reached 126 million yuan, up 8.99 percent, and revenue from animal and plant microecological preparations reached 33.5617 million yuan, up 21.12 percent. However, revenue from compound food additives was only 9.2892 million yuan, down sharply by 48.97 percent. The decline in performance was mainly due to depreciation during the ramp-up period of new production capacity and increased expenses from personnel reserves. Administrative expenses rose 41.01 percent, research and development expenses rose 32.73 percent, and selling expenses rose 27.82 percent. The company also launched a share buyback and advanced the commissioning of its smart factory, further improving its long-term production capacity layout.

Sci-Tech Bio released its 2026 interim report, with net profit attributable to the parent company at 25.10 million yuan, down 39.09% from the same period last year. Total operating revenue was 170 million yuan, and net cash flow from operating activities was 10.16 million yuan, down 63.55% year-on-year. The latest asset-liability ratio was 11.64%, gross margin was 47.09%, return on equity was 1.40%, and diluted earnings per share was 0.10 yuan.